Review
Copyright ©The Author(s) 2024.
World J Transplant. Jun 18, 2024; 14(2): 90382
Published online Jun 18, 2024. doi: 10.5500/wjt.v14.i2.90382
Table 1 The estimated risk of hepatitis C virus transmission and sustained virologic response rate in hepatitis C virus negative liver transplantation recipients of hepatitis C virus viremic and non-viremic donors
Ref.
Study design
Study group
Post LT viremia n/N (%)
SVR12
Time from transplant to start of DAA (d)
Luckett et al[38], 2019 Prospective 55 HCV non-viremic candidates received HCV Ab+/NAT- LT, including 6 SLKT5/53 (9)4/5 SVR12NA
Kwong et al[49], 2019Single-center, retrospective 10 HCV non-viremic candidates received HCV NAT+ LT10/10 (100)10/10 SVR12Median 43 (IQR 20–59)
Ting et al[50], 2019Single-center, retrospective 6 seronegative candidates received HCV NAT+ LT, including 2 SLKT6/6 (100)3/6 SVR12Median 37 (range 9-74)
1/6 completed DAA
2/6 ongoing DDA
Bethea et al[51], 2020Single-center, prospective 14 HCV negative recipients, including 4 SLKT:
9 received HCV NAT+ LT 9/9 (100)9 SVR12Range 0-29
5 received HCV Ab+/NAT- LT1/5 (20)NA
Kapila et al[52], 2020Single-center, retrospective 26 HCV negative recipients:
20 received HCV NAT+ LT 20/20 (100)11/20 SVR12Median 51 (range 19-121)
3/20 completed DAA
5/20 ongoing DAA
1/20 pending insurance approval
6 received HCV Ab+/NAT- LT2/5 (40)1/5 SVR12
1/5 ongoing DAA
Anwar et al[34], 2020Single-center, prospective, matched cohort trial32 NAT- recipients received HCV NAT+ LT, including 7 SLKT31/31 (100)19/30 SVR12Median 47 (IQR 18-140)
6/30 ETR
5/30 ongoing DAA
1/30 is yet to start treatment
Crismale et al[33], 2020 Single-center prospective observational 19 HCV negative recipients, including 4 SLKT:
13 received HCV NAT+ LT 13/13 (100)12/13 SVR12Median 42 (IQR 35-118)
6 received HCV Ab+/NAT- LT0/6 (0)
Aqel et al[32], 2021 Multicenter, prospective study34 HCV negative recipients, including 6 SLKT: Median 27.5
20 received HCV NAT+ LT20/20 (100)20/20 SVR12
14 received HCV Ab+/NAT- LT0/14 (0)
Sobotka et al[37], 2021Single-center, retrospective 42 HCV-seronegative recipients:
21 received HCV NAT+ LT 20/21 (95)15/15 (patients with data) SVR12Mean 38
21 received HCV Ab+/NAT- LT, including 1 SLKT2/21 (9.5)2/2 SVR12
Bohorquez et al[53], 2021Single-center, retrospective, case-control study61 HCV negative recipients, including 3 SLKT, received HCV NAT+ LT60/61 (98.3)51/56 SVR12Median 66.9 (IQR, 36-68.5)
5/56 ongoing DDA when study published
Hudson et al[36], 2021Single-center, retrospective 18 HCV negative recipients, including received HCV NAT+ LT18/18 (100)18/18 SVR12mean ± SD, 48 ± 23
Terrault et al[15], 2021Multicenter (6 US centers), prospective study13 HCV non-viremic candidates received HCV NAT+ LT13/13 (100)13/13 SVR12Median 7 (IQR 6-12)
Nair et al[104], 2021Retrospective cohort 23 HCV negative recipients received an HCV Ab+/NAT+ LT23/23 (100)23/23 SVR12Median 118 (IQR 46-129)
Bova et al[35], 2022Single-center, retrospective 29 HCV-negative recipients received HCV-viremic or HCV-seropositive LT, including 4 SLKT29/29 (100)NAMedian 29 (range 0-84)